

ChemoCentryx, Inc. Investor Relations Department 850 Maude Avenue Mountain View, CA 94043 United States

Visit IR website ☐ Sign-up for Email alerts ☐ ☐

NASDAQ: CCXI Last Trade: 6.87 Trade Time: 4:00 PM ET Aug 18, 2017 Change: -0.12 ♣ (-1.717%) Day Range 6.81 - 7.23 52-Week Range 4.17 - 10.80 Volume 141,943

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ChemoCentrvx is a biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases. inflammatory disorders and cancer. Our drug candidates target specific chemokines or chemoattractant receptors, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected. Our goal is to discover, develop and commercialize therapeutics with distinct advantages over currently marketed therapies in our disease areas of focus, thereby maximizing ... (more)

Stock Performance



Press Releases [View all]

Aug 8, 2017

<u>ChemoCentryx Reports Second Quarter</u> <u>2017 Financial Results and Recent Highlights</u>

Jul 26, 2017

ChemoCentryx to Hold Second Quarter 2017
Financial Results Conference Call on
Tuesday, August 8, 2017

Jun 6, 2017

Oral Presentations at ERA-EDTA Congress
Highlight Fourth Potential Indication for
Avacopan and Potential for CCR2 Inhibition
in Focal Segmental Glomerulosclerosis
(FSGS)

May 24, 2017

ChemoCentryx to Present at Two Upcoming Investor Conferences

May 23, 2017

ChemoCentryx Granted EU Orphan Drug
Designation for Avacopan in the Treatment
of Debilitating Kidney Disease C3
Glomerulopathy (C3G)

Financials [View all]

Mar 14, 2017 Annual Report (10-K)

Apr 10, 2017
Proxy Statement (DEF 14A)

Aug 8, 2017
Quarterly Report (10-Q)

May 10, 2017 Quarterly Report (10-Q)

Nov 8, 2016
Quarterly Report (10-Q)